Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional non-dolutegravir antiretroviral exposure had higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.23 in MarketScan and 1.11 i

Effect: decline; aRR 1.11; CI: 95% CI 1.07-1.15

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55